WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NVO

Based on 5 analysts offering 12 month price targets for Novo Nordisk A S

Min Forecast
$46.00-5.99%
Avg Forecast
$57.40+17.31%
Max Forecast
$70.00+43.06%

Should I buy or sell NVO stock?

Based on 5 analysts offering ratings for Novo Nordisk A S.

Buy
Strong Buy
3 analysts 60%
Buy
0 analysts 0%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
1 analysts 20%
Although NVO's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NVO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NVO stock forecasts and price targets.

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-09
lockedlocked$00.00+00.00%2025-11-28
lockedlocked$00.00+00.00%2025-11-25Find Out Why
lockedlocked$00.00+00.00%2025-10-02Find Out Why
lockedlocked$00.00+00.00%2025-09-29Find Out Why
TD Cowen
Bottom 17%
17
Strong BuyMaintains$70.00+43.06%2025-08-19Find out why

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?

Company
371.88%
Industry
275.71%
Market
238.37%
NVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?

Company
132.92%
Industry
114.68%
NVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$22.78+528.23%
Avg 2 year Forecast
$24.20+567.28%
Avg 3 year Forecast
$28.37+682.33%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$312.2B+542.46%
Avg 2 year Forecast
$333.5B+586.22%
Avg 3 year Forecast
$374.3B+670.34%
NVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?

Company
95.81%
Industry
61.98%
Market
39.85%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?

Company
95.94%
Industry
119.45%
Market
23.3%
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVO$48.93$57.40+17.31%Buy
VRTX$465.02$529.92+13.96%Strong Buy
REGN$783.65$820.32+4.68%Buy
ARGX$833.54$1,028.44+23.38%Strong Buy
ALNY$308.48$489.95+58.83%Strong Buy
View Top Biotech Stocks

Novo Nordisk (Ozempic) Stock Forecast FAQ

Is Novo Nordisk (Ozempic) Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: NVO) stock is to Buy NVO stock.

Out of 5 analysts, 3 (60%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 1 (20%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 1 (20%) are recommending NVO as a Strong Sell.

If you're new to stock investing, here's how to buy Novo Nordisk (Ozempic) stock.

What is NVO's earnings growth forecast for 2026-2028?

(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual earnings growth rate of 95.81% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.98%, and it is also forecast to beat the US market's average forecast earnings growth rate of 39.85%.

Novo Nordisk (Ozempic)'s earnings in 2026 is $16,207,911,392.On average, 27 Wall Street analysts forecast NVO's earnings for 2026 to be $101,710,467,500, with the lowest NVO earnings forecast at $88,826,710,000, and the highest NVO earnings forecast at $129,864,525,000. On average, 24 Wall Street analysts forecast NVO's earnings for 2027 to be $108,033,354,000, with the lowest NVO earnings forecast at $88,914,224,000, and the highest NVO earnings forecast at $141,210,090,000.

In 2028, NVO is forecast to generate $126,659,994,500 in earnings, with the lowest earnings forecast at $96,569,466,500 and the highest earnings forecast at $144,788,341,000.

What is NVO's revenue growth forecast for 2026-2028?

(NYSE: NVO) Novo Nordisk (Ozempic)'s forecast annual revenue growth rate of 95.94% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 119.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.3%.

Novo Nordisk (Ozempic)'s revenue in 2026 is $48,902,531,645.On average, 27 Wall Street analysts forecast NVO's revenue for 2026 to be $1,393,986,395,000,000, with the lowest NVO revenue forecast at $1,245,860,020,000,000, and the highest NVO revenue forecast at $1,646,031,180,000,000. On average, 24 Wall Street analysts forecast NVO's revenue for 2027 to be $1,488,925,690,000,000, with the lowest NVO revenue forecast at $1,268,135,905,000,000, and the highest NVO revenue forecast at $1,723,525,720,000,000.

In 2028, NVO is forecast to generate $1,671,459,355,000,000 in revenue, with the lowest revenue forecast at $1,457,099,170,000,000 and the highest revenue forecast at $1,847,014,225,000,000.

What is NVO's forecast return on assets (ROA) for 2026-2029?

(NYSE: NVO) forecast ROA is 132.92%, which is higher than the forecast US Biotechnology industry average of 114.68%.

What is NVO's Price Target?

According to 5 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is $57.40, with the highest NVO stock price forecast at $70.00 and the lowest NVO stock price forecast at $46.00.

On average, Wall Street analysts predict that Novo Nordisk (Ozempic)'s share price could reach $57.40 by Nov 28, 2026. The average Novo Nordisk (Ozempic) stock price prediction forecasts a potential upside of 17.31% from the current NVO share price of $48.93.

What is NVO's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: NVO) Novo Nordisk (Ozempic)'s current Earnings Per Share (EPS) is $3.65. On average, analysts forecast that NVO's EPS will be $22.78 for 2026, with the lowest EPS forecast at $19.89, and the highest EPS forecast at $29.09. On average, analysts forecast that NVO's EPS will be $24.20 for 2027, with the lowest EPS forecast at $19.91, and the highest EPS forecast at $31.63. In 2028, NVO's EPS is forecast to hit $28.37 (min: $21.63, max: $32.43).

What is NVO's forecast return on equity (ROE) for 2026-2029?

(NYSE: NVO) forecast ROE is 371.88%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.